P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study

[Grebely, J.; Hajarizadeh, B.; Amin, J.; Marks, P.; Quiene, S.; Dore, G. J.] UNSW Australia, Kirby Inst, Sydney, NSW, Australia. [Dalgard, O.] Akershus Univ Hosp, Oslo, Norway. [Conway, B.] Vancouver Infect Dis Ctr, Vancouver, BC, Canada. [Foster, G.] Queen Marys Univ London, Liver Unit, London, England. [Bruggmann, P.] Arud Ctr Addict Med, Zurich, Switzerland. [Backmund, M.] Univ Munich, Munich, Germany. [Robaeys, G.] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Genk, Belgium. [Robaeys, G.] UZLeuven, Dept Hepatol, Leuven, Belgium. [Robaeys, G.] UHasselt, Hasselt, Belgium. [Swan, T.] Treatment Act Grp, New York, NY USA. [Weltman, M.] Nepean Hosp, Sydney, NSW, Australia. [Shaw, D.] Royal Adelaide Hosp, Adelaide, SA 5000, Australia. [Dunlop, A.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Hellard, M.] Burnet Inst, Melbourne, Vic, Australia. [Bruneau, J.] Univ Montreal, Montreal, PQ, Canada. [Bourgeois, S.] Stuivenberg ZNA, Antwerp, Belgium. [Thurnheer, C.] Univ Hosp Bern, Div Infect Dis, CH-3010 Bern, Switzerland. [Thurnheer, C.] Univ Bern, Bern, Switzerland.